Asia-Pacific peripheral neuropathy treatment market is estimated to grow at a CAGR of 5.1% during the forecast period. Rising incidences of diabetes is the major factor accelerating market growth. As per the Asian Diabetes Prevention Initiative, 60% of the diabetic population across the globe live in Asia. In China, total cases of diabetes in adults was nearly 116.4 million in 2019, while in India, it was nearly 77 million in 2019. The most common diabetic complication is peripheral neuropathy. It is a severe diabetic complication that may affect nearly 50% of people suffering from diabetes. This condition affects the legs and feet first and is followed by hands and arms. Several prescription medications are available for diabetes-associated nerve pain. Some antidepressants provide ease to nerve pain. Tricyclic antidepressants may support mild to moderate nerve pain. This class of drugs includes imipramine (Tofranil), amitriptyline, and desipramine (Norpramin).

Asia-Pacific peripheral neuropathy treatment market is segmented based on type and application. Based on type, the market is classified into antidepressants, pain relievers, antiseizure, and others. Based on the application, the market is classified into diabetes, chemotherapy-induced, and others. Increasing cancer prevalence is resulting in an increasing demand for chemotherapy in the region. As per the World Health Organization (WHO), in 2018, the number of new cancer incidences reported in the South-East Asia region was nearly 2 million. This results in an increasing demand for chemotherapy which is most often used for cancer treatment. Chemotherapy may lead to the degeneration of motor nerves and peripheral sensory. It has been anticipated to be high in patients who received treatment with any neurotoxic chemotherapeutic agent. Chemotherapy-induced peripheral neuropathy is normally treated with analgesics, antidepressants, and anticonvulsants. 

Some prominent players in the market include Alembic Pharmaceuticals Ltd., Cipla Ltd., Daiichi Sankyo Company, Ltd., and Pfizer Inc. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in April 2019, Daiichi Sankyo Company, Ltd. declared the launch of Tarlige tablets 2.5 mg, 5 mg, 10 mg, 15 mg for pain treatment in Japan. ?2? ligand is a drug that is developed by Daiichi Sankyo, was approved in Japan for marketing in January 2019 based on phase 3 clinical trials results performed in Asia which includes Japan in patients suffering from diabetic peripheral neuropathic pain, postherpetic neuralgia (PHN), for treatment of peripheral neuropathic pain.

Research Methodology

The market study of the Asia-Pacific peripheral neuropathy treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Asia-Pacific Peripheral Neuropathy Treatment Market Research and Analysis by Type
2. Asia-Pacific Peripheral Neuropathy Treatment Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the Asia-Pacific peripheral neuropathy treatment market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Asia-Pacific peripheral neuropathy treatment market.
• Insights about market determinants which are stimulating the Asia-Pacific peripheral neuropathy treatment market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.